Sanofi's launch of Xyzal Allergy 24HR in the US helped remedy its slumping consumer health product business with more than $43m sales in the first quarter as the division's overall revenues grew nearly 5% to $1.5bn.
The French pharma's strategy of driving consumer health business growth by expanding the product lineup played out during the first...






